Figure 5
In vivo activity tests of htFGF21. HFD-fed mice were injected with htFGF21 intraperitoneally at doses of 0 (vehicle), 1, or 10 mg/kg once daily for 14 days. NCD-fed mice were included as controls and injected intraperitoneally with vehicles. (A) Changes in body weight throughout the injection. (B) Percent weight gains on the following day after the last injection. (C) Effects of the injection on liver TG contents. (D) H&E and Oil Red O staining of liver sections showing reversal of vacuolation and lipid accumulation in htFGF21-injected HFD-fed mice. Data are represented as mean ± SEM, calculated using one-way ANOVA followed by Tukey’s multiple comparisons test, *p < 0.05, **p < 0.01, *** and †††p < 0.001, **** and ††††p < 0.0001. n = 5–6 mice/group. ††† and †††† indicate vehicle-injected NCD-fed mice versus vehicle-injected HFD-fed mice. *, **, ***, and **** indicate vehicle-injected HFD-fed mice versus htFGF21-injected HFD-fed mice. Scale bars: 100 μm (H&E), 50 μm (Oil Red O).
